The University of Chicago Header Logo

Connection

Peter O'Donnell to Piperazines

Back to Details
This is a "connection" page, showing publications Peter O'Donnell has written about Piperazines.
Peter O'Donnell
Connection Strength
0.042
Piperazines
  1. Phase II Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations. JCO Precis Oncol. 2023 07; 7:e2300095.
    View in: PubMed
    Score: 0.042
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.